Hyderabad: The Central Drugs Standards Control Organisation (CDSCO), India's drug regulator, has approved the extension of the shelf life of the indigenously developed Covid-19 vaccine Covaxin from nine to twelve months. Bharat Biotech, based in Hyderabad, announced on Wednesday that the CDSCO had approved an extension of the vaccine's shelf life to 12 months from the date of manufacture.

"This shelf life extension has been approved based on the availability of additional stability data that was submitted to the CDSCO. Our stakeholders have been informed of the shelf life extension "According to the vaccine manufacturer. It was first granted permission to sell and distribute Covaxin, which has a six-month shelf life when stored at two to eight degrees Celsius.

After Bharat Biotech submitted updated accelerated and real-time stability data for Covaxin, the CDSCO approved an extension of the shelf life to nine months. Covaxin and Covishield, both made by Serum Institute of India, are the two vaccines currently being used in India's Covid-19 vaccination campaign, which began in January. In India, the Russian vaccine Sputnik-V has been approved for emergency use.

India-made covaxin may be given green signal today WHO

Australia recognises Covaxin for establishing traveller's inoculation status

WHO to mull over emergency use listing of Covaxin based on today's meeting